Thiazide diuretics versus loop diuretics in stage 3-5 CKD: impact on cardiorenal outcomes.
Li-Chin SungHui-Wen ChiuSamuel Mon-Wei YuLiam Li-An TsouYung-Ho HsuMai-Szu WuCheng-Li LinFuu-Jen TsaiChu-Lin ChouPublished in: Postgraduate medicine (2024)
Among stage 3-5 CKD patients on ACEIs/ARBs, loop diuretics exposure was associated with increased mortality and hospitalization for cardiorenal events, while thiazide diuretics exposure in isolation had no such associations. In the present data, we cannot evaluate the relationship between furosemide-associated adverse outcomes and worse renal function. These findings highlight the need for randomized controlled trials to assess the safety of loop diuretics in this population, urging caution in their prescription without a clear clinical indication.
Keyphrases
- chronic kidney disease
- end stage renal disease
- transcription factor
- randomized controlled trial
- newly diagnosed
- ejection fraction
- prognostic factors
- cardiovascular disease
- peritoneal dialysis
- systematic review
- electronic health record
- clinical trial
- type diabetes
- patient reported outcomes
- coronary artery disease
- big data
- machine learning
- study protocol
- deep learning